Enzymatic Amidation for HMG-CoA Inhibitor Intermediates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for the industrial-scale preparation of pentanoic acid derivatives and their conversion to HMG-CoA reductase inhibitors face challenges such as low yields and impurities, particularly in the use of chiral auxiliaries and cryogenic conditions.
Innovation Solution
A novel process involving enzymatic enantioselective amidation, transesterification, hydroxy group protection, and catalytic hydrogenation to produce pentanoic acid derivatives efficiently, using immobilized Candida antarctica lipase B and titanium catalysts, which avoids the need for chiral auxiliaries and cryogenic conditions, resulting in higher yields of optically pure compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If chiral auxiliaries and cryogenic conditions are used in the preparation of pentanoic acid derivatives, then optical purity is improved, but manufacturing complexity and cost increase
Solution Approach 1:
The patent replaces mechanical/chemical resolution methods with enzymatic resolution using lipase. The enzyme naturally provides chiral recognition and selectivity, eliminating the need for complex chiral auxiliaries and cryogenic conditions while maintaining high optical purity in the preparation of pentanoic acid derivatives
Solution Approach 2:
The patent changes the reaction conditions from cryogenic temperatures to ambient or mild temperatures by using enzymatic catalysis. The lipase enzyme maintains high activity and selectivity under these milder conditions, simplifying the process while achieving the same optical purity outcomes
2Manufacturing precision
If conventional resolution methods are used for racemate separation, then optical purity is achieved, but yield is reduced due to impurities
Solution Approach 1:
The patent substitutes conventional chemical resolution methods with enzymatic resolution using lipase. The enzyme provides high enantioselectivity that simultaneously achieves both high optical purity and high yield by selectively transforming one enantiomer while leaving the other unchanged, avoiding the formation of difficult-to-remove impurities
Solution Approach 2:
The lipase enzyme performs self-selective catalysis where it naturally recognizes and acts on only one enantiomer of the racemic mixture. This self-service capability of the enzyme system achieves both high purity and high yield without requiring additional purification steps that would reduce overall yield
3Manufacturing precision
If chiral auxiliaries are used in asymmetric synthesis, then optical purity is improved, but manufacturing cost and complexity increase
Solution Approach 1:
The patent replaces the need for chiral auxiliaries with enzymatic catalysis. The lipase enzyme inherently provides the chiral environment needed for asymmetric synthesis, eliminating the need to introduce, attach, and remove chiral auxiliary groups, thereby simplifying the manufacturing process while maintaining high optical purity
Solution Approach 2:
The patent extracts the chiral recognition function from complex chiral auxiliary systems and concentrates it in the biocatalytic active site of the lipase enzyme. This extraction simplifies the overall system by removing the need for stoichiometric chiral auxiliaries and their associated handling complexities
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process enhances the scalability and cost-effectiveness of producing pentanoic acid derivatives and their conversion to HMG-CoA reductase inhibitors, achieving higher yields and improved chemical and optical purity.
Implementation Method 1
enzymatic enantioselective amidation of compound of Formula-III in presence of suitable enzyme to get amide compound of Formula-IV
Implementation Method 2
using immobilized Candida antarctica lipase B
Implementation Method 3
transesterification of compound of Formula-IV into compound of Formula-V
Implementation Method 4
catalytic hydrogenation to produce pentanoic acid derivatives efficiently
Data Source
AI summary
The present invention relates to an improved process for the preparation of compound of Formula-II, which is an intermediate in the preparation of HMG-CoA reductase inhibitors.wherein X is hydrogen or hydroxy protecting group and R1 is carboxyl protecting group.